Naringenin Decreases Progression of Atherosclerosis by Improving Dyslipidemia in High-Fat–Fed Low-Density Lipoprotein Receptor–Null Mice

Abstract

These in vivo studies demonstrate that the citrus flavonoid naringenin ameliorates the dyslipidemia in Western-fed low-density lipoprotein receptor-null mice, leading to decreased atherosclerosis; and suggests a potential therapeutic strategy for the hyperlipidemia and increased risk of atherosclerosis associated with insulin resistance.